Scarica l'app Stockscreener
77.70
0.30%
-0.23
Dopo l'orario di chiusura:
77.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$77.93
Aprire:
$78
Volume 24 ore:
1.56M
Relative Volume:
0.58
Capitalizzazione di mercato:
$15.06B
Reddito:
$502.08M
Utile/perdita netta:
$-732.94M
Rapporto P/E:
-20.53
EPS:
-3.7842
Flusso di cassa netto:
$-455.50M
1 W Prestazione:
+4.80%
1M Prestazione:
+11.94%
6M Prestazione:
+37.21%
1 anno Prestazione:
+126.93%
Intervallo 1D:
$76.17
$78.90
Intervallo di 1 settimana:
$73.14
$79.50
Portata 52W:
$31.77
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
77.70 | 15.11B | 502.08M | -732.94M | -455.50M | -3.7842 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-03-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-11 | Iniziato | Bernstein | Outperform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
BridgeBio Pharma(BBIO.US) Officer Sells US$5.97 Million in Common Stock - Moomoo
BridgeBio Pharma CEO Sells $2.98M in Stock - National Today
BridgeBio Pharma CEO Kumar sells $5.9m in BBIO stock - Investing.com
BridgeBio (BBIO) CEO-linked family trusts sell 80,000 shares under 10b5-1 plan - Stock Titan
Dip Buying: Will BridgeBio Pharma Inc benefit from government policyMarket Performance Summary & Weekly High Return Opportunities - baoquankhu1.vn
Assessing BridgeBio Pharma (BBIO) Valuation After Key ATTR-CM And LGMD2I/R9 Milestones - simplywall.st
BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout - ChartMill
BBIO (BridgeBio Pharma) PE Ratio : At Loss (As of Apr. 11, 2026) - GuruFocus
RBC Forecasts 35% Upside For BridgeBio Pharma Stock Following Attruby Drug Success - TIKR.com
RBC Capital initiates coverage of BridgeBio Pharma (BBIO) with outperform recommendation - MSN
BridgeBio Submits NDA for BBP-418 in LGMD2I/R9, Potentially the First Approved Therapy for Any Form of Limb-Girdle Muscular Dystrophy - NeurologyLive
120,000-share Form 144; BBIO insiders report 10b5-1 sales (BBIO) - Stock Titan
BridgeBio Pharma (BBIO) Receives Positive Analyst Coverage from RBC Capital | BBIO Stock News - GuruFocus
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Strength And Late Stage Pipeline Focus - Yahoo Finance
RBC Initiates BridgeBio Pharma at Outperform, Speculative Risk With $100 Price Target - Moomoo
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157 - Moomoo
RBC Capital Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $100 - Moomoo
RBC Capital initiates BridgeBio Pharma stock at Outperform with $100 target - Investing.com India
(BBIO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Sentiment Watch: Should you buy the dip on BridgeBio Pharma Inc2026 Big Picture & AI Powered Market Entry Ideas - baoquankhu1.vn
Market Rankings: Will BridgeBio Pharma Inc benefit from green energy policies2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
BridgeBio Pharma, Inc. (BBIO) Stock forecasts - Yahoo Finance UK
BBIO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Possible Bearish Signals With BridgeBio Pharma Insiders Disposing Stock - Moomoo
BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com India
Viking funds hold 6.1% of BridgeBio Pharma (NASDAQ: BBIO) - Stock Titan
BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com
BBOT SEC FilingsBridgeBio Oncology Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), 60 Degrees Pharmaceuticals, Inc. (SXTP) and BridgeBio Pharma (BBIO) - The Globe and Mail
Bond Watch: Is BridgeBio Pharma Inc stock a value trapEarnings Trend Report & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Allspring Global Investments Holdings LLC Has $77.78 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - marketbeat.com
Sentiment Review: Will BridgeBio Pharma Inc benefit from green energy policies2026 Biggest Moves & Low Volatility Stock Recommendations - baoquankhu1.vn
Mizuho Lifts PT on BridgeBio Pharma (BBIO) to $106 From $91 – Here’s Why - Insider Monkey
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Bridgebio asks FDA to approve potential 1st treatment for LGMD2i - Muscular Dystrophy News
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $111 - Moomoo
BridgeBio's rare-disease pipeline sparks growth buzz - MSN
INVESCO Small Cap Equity Fund's BridgeBio Pharma Inc(BBIO) Holding History - GuruFocus
Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio submits NDA for oral BBP-418 to treat LGMD2I/R9 - Investing.com Australia
BridgeBio Files NDA for LGMD2I/R9 Oral Therapy - TipRanks
BridgeBio (BBIO) Shares Promising Long-Term Acoramidis Data at A - GuruFocus
BridgeBio (BBIO) Submits Application for New Muscular Dystrophy Treatment - GuruFocus
BridgeBio (NASDAQ: BBIO) files NDA for first potential LGMD2I/R9 treatment - stocktitan.net
BridgeBio reports sustained mortality benefits for acoramidis at 54 months By Investing.com - Investing.com Canada
BridgeBio Pharma Announces Sustained Clinical Benefits of Acoramidis in Long-Term ATTRibute-CM Trial - Quiver Quantitative
BridgeBio Pharma, Inc. Presents Long-Term Efficacy and Safety Data from the ATTRibute-CM Open-Label Extension Trial - marketscreener.com
Jefferies reiterates Buy on BridgeBio Pharma stock, $100 target By Investing.com - Investing.com Canada
BridgeBio submits NDA to FDA for BBP-418 for individuals living with LGMD2I/R9 - marketscreener.com
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9 - manilatimes.net
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bridgebio Pharma Inc Azioni (BBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Apr 10 '26 |
Sale |
74.60 |
40,000 |
2,984,172 |
595,686 |
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):